Steven Cohen Neoleukin Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.4 - $0.55 $771,018 - $1.06 Million	-1,927,547 Reduced 93.38%	136,675 $69,000
Q3 2022 Nov 14, 2022	BUY	$0.69 - $1.33 $432,495 - $833,650	626,805 Added 43.61%	2,064,222 $1.32 Million
Q2 2022 Aug 15, 2022	BUY	$0.92 - $2.25 $195,423 - $477,938	212,417 Added 17.34%	1,437,417 $1.48 Million
Q1 2022 May 16, 2022	BUY	$1.72 - $5.23 $368,441 - $1.12 Million	214,210 Added 21.19%	1,225,000 $2.3 Million
Q4 2021 Feb 14, 2022	BUY	$4.65 - $7.75 $50,173 - $83,622	10,790 Added 1.08%	1,010,790 $4.87 Million
Q3 2021 Nov 15, 2021	BUY	$6.05 - $9.66 $707,232 - $1.13 Million	116,898 Added 13.24%	1,000,000 $7.23 Million
Q2 2021 Aug 16, 2021	SELL	$9.23 - $13.12 $3.93 Million - $5.58 Million	-425,498 Reduced 32.52%	883,102 $8.15 Million
Q1 2021 May 17, 2021	BUY	$11.26 - $15.78 $1.27 Million - $1.78 Million	112,875 Added 9.44%	1,308,600 $16.1 Million
Q4 2020 Feb 16, 2021	BUY	$10.17 - $14.56 $1.99 Million - $2.85 Million	196,031 Added 19.61%	1,195,725 $16.9 Million
Q3 2020 Nov 16, 2020	BUY	$9.68 - $17.01 $4.92 Million - $8.65 Million	508,698 Added 103.61%	999,694 $12 Million
Q2 2020 Aug 14, 2020	SELL	$9.95 - $17.05 $1.1 Million - $1.88 Million	-110,197 Reduced 18.33%	490,996 $8.15 Million
Q1 2020 May 15, 2020	BUY	$6.12 - $13.64 $2.9 Million - $6.47 Million	474,411 Added 374.19%	601,193 $6.84 Million
Q4 2019 Feb 14, 2020	BUY	$2.65 - $12.72 $335,972 - $1.61 Million	126,782 New	126,782 $1.56 Million

199K

Ticker NLTX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 42,579,900
Description
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of vario...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.